Alteplase (Actilyse), the first treatment for acute ischaemic stroke has been launched in the EU. Actilyse, a recombinant form of tissue plasminogen activator, is approved for use in stroke patients within a 0-3 hour treatment window.
A National Institute of Neurological Disorders and Stroke trial in 1995 reported that the average length of hospital stay was significantly shorter in alteplase-treated patients. In addition, those receiving alteplase within the three hour treatment window were at least 30% more likely to have minimal or no disability three months after their stroke. A new trial looking at Actilyse’s efficacy in the 3-4 hour treatment window is due to start enrolling patients in the next few weeks across Europe.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!